Why is everyone talking about GLP-1s and not SGLT2 inhibitors in 2026
The age and ethnicity profiles, and the range of obesity measures, of participants included in these studies, limit the generalizability of the findings, especially to ethnic minority groups, other age groups, people with severe or treatment-resistant obesity, and psychiatric illness
Innovative Primary Care has a new GLP weight loss program, and we often get asked to explain the science behind GLPs and weight loss
While experiencing a faster heartbeat during exercise is generally normal, understanding the difference between a typical response and a potential problem is essential
The oral form is often chosen for gut-related goals, on the rationale that it acts on the GI lining as it passes through the digestive tract though this rationale comes from animal research, and BPC-157 has not been shown in human trials to treat any specific gastrointestinal condition